Drug intelligence / Profile preview

VIS571

Development stage: Unknown
Lead developer: Otsuka Holdings
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

VIS571 is a monoclonal antibody developed by Visterra, a subsidiary of Otsuka, currently in Phase 1 clinical development for the treatment of autoimmune-related diseases. It is designed to target the interleukin-2 receptor (IL2R) to modulate IL-2 signaling pathways. Unlike VIS171, which is a modified IL-2 molecule (mIL-2), VIS571 is an antibody-based therapeutic candidate generated using Visterra's Hierotope platform. The drug aims to restore immune homeostasis by selectively influencing the activity of T lymphocyte populations involved in autoimmune pathology.

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on VIS571.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIS571.

Explore the full profile